Supratherapeutic doses of rEPO have proven to reduce tubular atrophy, glomerular sclerosis, and fibrosis by downregulating the expression of profibrogenic proteins TGF-β, Smad 2/3 in a unilateral ureteral obstruction model of kidney disease [33]. This evidence concerns the gene TGFB1 and glomerulosclerosis.